Fig 1: Immunofluorescence analysis of ATP5H and COX17 in control and ET-1 treated RGCs. Immunostaining for (a) COX17 (red) and (b) ATP5H (magenta) in primary RGCs. Scale bar, 50 μm and quantitation of COX17 and ATP5H (c,d) from five different images (n = 5) following ET-1 treatment. Quantitation of fluorescence intensity of COX17 and ATP5H calculated as integrated density/Brn3a positive 100 cells as determined from the five different images. Data are expressed as Mean±SEM (*P < 0.05).
Fig 2: ATP5H and COX17 expression in Morrison’s model of ocular hypertension following 2 week IOP elevation. (a) Representative graph of IOP measurements for IOP elevated (white circles) and contralateral control (black circles) eyes in adult female Brown Norway rats. (b) Representative confocal microscopy images. Immunostaining of retina sections probed for ATP5H (green), COX17 (red), Brn3a (cyan) following 2 weeks of IOP elevation. C) Quantitation of the Relative fluorescent intensity for (c) COX17 and D) ATP5H estimated by quantifying only Brn3a positive cells. Scale bar = 50 μm. Bars represent Mean ± SEM (n = 3 animals/group).
Fig 3: ATP5H and COX17 expression in retinas of adult Brown Norway rats following intravitreal administration of ET-1. (a) Representative images. Immunostaining of retina sections probed for ATP5H (yellow) and COX17 (red) following ET-1, 500 (μM) intravitreal injection 24 hours. Scale bar, 50 μm. Relative fluorescent intensity for ATP5H (b) and COX17 (c) for the NFL; GC and IPL. Bars represent mean ± SEM (n = 6 animals/group). Asterisks indicate statistical significance *p <0.05; **p <0.01; by student’s t-test. ONL outer nuclear layer, OPL outer plexiform layer, INL inner nuclear layer, IPL inner plexiform layer, GCL ganglion cell layer, NFL nerve fiber layer.
Supplier Page from Abcam for Anti-ATP5H antibody [7F9BG1]